HealthDay (6/8, Norton) reports that research suggests “AD/HD medications might help lessen the risk of suicide in children with serious behavioral issues.” Investigators “found that medications like Ritalin [methylphenidate] and Adderall [amphetamine-dextroamphetamine], commonly prescribed for attention-deficit/hyperactivity disorder (AD/HD), were linked to a lower risk of suicidal behavior among 9- and 10-year-olds with substantial ‘externalizing’ symptoms.” The findings were published in JAMA Network Open.

Related Links:

— “ADHD Meds May Help Keep Some Kids From Thoughts of Suicide ” Amy Norton, HealthDay, June 8, 2021

HCPlive (6/8, Walter) reports, “As the COVID-19 pandemic continued, physician visits for individuals with postpartum mental illnesses were significantly higher than what was expected based on prepandemic data,” investigators concluded after comparing “physician visit rates for postpartum mental illness in Ontario during the pandemic with rates that were expected based on prepandemic patterns.” The findingsof the “population-based, repeated cross-sectional study” were published online June 7 in CMAJ.

Related Links:

— “Increase in Postpartum Physician Visits During COVID-19 Pandemic “Kenny Walter, HCPlive, June 8, 2021

MedPage Today (6/7, Kneisel) reports, “Language development scores at age two were similar for children of women with epilepsy taking antiseizure medications and children with healthy mothers,” researchers concluded in an analysis that “included 292 children of women with epilepsy (median age of about 2, 53% girls) and 90 children of healthy women (median age of about 2, 52% boys).” According to the article, “most of the mothers with epilepsy were taking lamotrigine (Lamictal; 46%) or levetiracetam (Keppra; 33.2%),” and “about 45% were taking both.” The findings were published online in JAMA Neurology.

Related Links:

— MedPage Today (requires login and subscription)

HCPlive (6/7, Iopoce) reports researchers have “examined the frequency of use and persistent use of benzodiazepine” medications “in patients undergoing major and minor surgery.” After examining claims data from the Marketscan Database from “nearly 50 million enrollees with commercial insurance from 350 payers and six million Medicaid recipients from 12 states,” the research team “found that a small percentage of surgical patients receive benzodiazepine prescriptions, but one in five of these patients use the” medication “persistently.” The findings were published online June 3 in JAMA Network Open.

Related Links:

— “Perioperative Benzodiazepine Prescription Linked to Persistent Use in Surgical Patients “Connor Iapoce, HCPlive, June 7, 2021

HealthDay (6/7) reports, “Only 29 percent of children and adolescents with gender dysphoria receive a gender dysphoria-related diagnosis (GDRD), and 25 percent are prescribed gender-affirming hormonal treatment (GAHT),” investigators concluded in a study that included “958 gender-diverse children and adolescents who did not have a GDRD or GAHT at index.” Researchers then compared “the rates of first GDRD and first GAHT prescription.” The findings were published online June 7 in Pediatrics.

Related Links:

— “Diagnosis, Treatment of Gender Dysphoria Varies Among Children
“Physician’s Briefing Staff, HealthDay, June 7, 2021